Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
23andme Holding Co's Business Segments
23andme Holding Co's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
19
Largest Segment
Service
Total Revenue
$ 25
Countrys Reported
3
Revenue Share by Reportable Segment - FY
- Service83.9%
- PGS78%
- Consumer services71.7%
- Service Point in Time56.1%
- Consumer services Point in Time55.4%
- Service Over Time47.5%
- Consumer services Over Time45.8%
- PGS Over Time40.1%
- PGS Point in Time38%
- Research services27.3%
- Telehealth23.2%
- Telehealth Point in Time17.4%
- Telehealth Over Time5.8%
- United Kingdom5.7%
- Canada5.3%
- Other regions2.4%
- Research services Over Time1.6%
- Research services Related Party0.8%
- Research services Point in Time0.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 21 | 83.9% |
| PGS | $ 19 | 78% |
| Consumer services | $ 18 | 71.7% |
16 more segments available
Sign in to unlock the full 23andme Holding Co dataset.
Revenue Share by Country - FY
- United States90.3%
- United Kingdom5.7%
- Canada5.3%
Revenue by Geographic Country - FY
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| United States | $ 22 | 90.3% |
| United Kingdom | $ 1 | 5.7% |
| Canada | $ 1 | 5.3% |
Revenue by Product & Service Category - FY
- Service83.9%
- Consumer services55.4%
- PGS38%
- Product19.7%
- Health Care, Other17.4%
- Research services0.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 21 | 83.9% |
| Consumer services | $ 14 | 55.4% |
| PGS | $ 9 | 38% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full 23andme Holding Co dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Service83.9%
- PGS78%
- Consumer services71.7%
- Service Point in Time56.1%
- Consumer services Point in Time55.4%
- Service Over Time47.5%
- Consumer services Over Time45.8%
- PGS Over Time40.1%
- PGS Point in Time38%
- Research services27.3%
- Telehealth23.2%
- Telehealth Point in Time17.4%
- Telehealth Over Time5.8%
- United Kingdom5.7%
- Canada5.3%
- Other regions2.4%
- Research services Over Time1.6%
- Research services Related Party0.8%
- Research services Point in Time0.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 21 | 83.9% |
| PGS | $ 19 | 78% |
| Consumer services | $ 18 | 71.7% |
16 more segments available
Sign in to unlock the full 23andme Holding Co dataset.
Description of 23andme Holding Co
The company known as 23andMe Holding Co., previously named VG Acquisition Corp., is dedicated to assisting individuals in living healthier lives. Their goal is to help people access, comprehend and benefit from the human genome. They believe that their extensive database of genetic and phenotypic information can revolutionize healthcare. They obtain this data from millions of customers who separately consent to participate in their research. The company is committed to ethical, scientific, and privacy standards to provide trustworthy health and genetic information.
23andMe Holding Co. was the first to provide direct-to-consumer genetic testing, allowing individuals to have access to unique, personalized genetic health risks, ancestry, and traits. The company has multiple Food and Drug Administration ("FDA") authorizations for over-the-counter health and carrier status reports. 23andMe Holding Co. is the only company to obtain FDA authorization for all carrier status, genetic health risk, cancer predisposition, and pharmacogenetics reports. Customers can choose from over 60 health reports in the U.S.
In November 2021, 23andMe Holding Co. acquired Lemonaid Health, Inc., making personalized healthcare accessible for all. Lemonaid offers affordable and direct online access to medical care, from consultation through treatment, for a variety of common conditions, using evidence-based guidelines and clinical protocols to provide quality patient care. Patients can use the online pharmacy for fast and free delivery when prescribed medication by medical professionals.
The company operates in two reporting segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment includes the Personal Genome Service® (“PGS”), telehealth services, and research services. The PGS service provides customers with genetic reports on ancestral origins, personal genetic health risks, and the chances of passing on rare carrier conditions to their children. Customers can access PGS services on the website, 23andMe.com, or mobile app. Customers can upgrade from the Ancestry + Traits Service to the Health + Ancestry Service for a fee. 23andMe+ premium subscription service offers customers the Health + Ancestry Service, pharmacogenetic reports, personalized genetic risk reports, and advanced ancestry and health features. The company's research programs allow customers to participate voluntarily. 80% of customers have participated in the programs. The company analyzes the data provided by the customers and uses proprietary machine learning techniques to gain insight into how genetic variants affect the likelihood of individuals developing specific diseases.
The telehealth segment provides patients with medical consultation and treatment from one of their affiliated licensed physicians or nurse practitioners via telehealth. Patients can access the online pharmacy for fast and free delivery of non-controlled medications for acute and chronic conditions at affordable prices. The Consumer & Research Services segment accounts for the majority of the company's revenue.
23andMe Holding Co. was the first to provide direct-to-consumer genetic testing, allowing individuals to have access to unique, personalized genetic health risks, ancestry, and traits. The company has multiple Food and Drug Administration ("FDA") authorizations for over-the-counter health and carrier status reports. 23andMe Holding Co. is the only company to obtain FDA authorization for all carrier status, genetic health risk, cancer predisposition, and pharmacogenetics reports. Customers can choose from over 60 health reports in the U.S.
In November 2021, 23andMe Holding Co. acquired Lemonaid Health, Inc., making personalized healthcare accessible for all. Lemonaid offers affordable and direct online access to medical care, from consultation through treatment, for a variety of common conditions, using evidence-based guidelines and clinical protocols to provide quality patient care. Patients can use the online pharmacy for fast and free delivery when prescribed medication by medical professionals.
The company operates in two reporting segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment includes the Personal Genome Service® (“PGS”), telehealth services, and research services. The PGS service provides customers with genetic reports on ancestral origins, personal genetic health risks, and the chances of passing on rare carrier conditions to their children. Customers can access PGS services on the website, 23andMe.com, or mobile app. Customers can upgrade from the Ancestry + Traits Service to the Health + Ancestry Service for a fee. 23andMe+ premium subscription service offers customers the Health + Ancestry Service, pharmacogenetic reports, personalized genetic risk reports, and advanced ancestry and health features. The company's research programs allow customers to participate voluntarily. 80% of customers have participated in the programs. The company analyzes the data provided by the customers and uses proprietary machine learning techniques to gain insight into how genetic variants affect the likelihood of individuals developing specific diseases.
The telehealth segment provides patients with medical consultation and treatment from one of their affiliated licensed physicians or nurse practitioners via telehealth. Patients can access the online pharmacy for fast and free delivery of non-controlled medications for acute and chronic conditions at affordable prices. The Consumer & Research Services segment accounts for the majority of the company's revenue.
23andMe Holding Co: Comprehensive Overview
23andMe Holding Co is a pioneering biotechnology and genetic testing company that focuses on empowering individuals to understand their genetic information, emphasizing health and ancestry insights. The company offers a multifaceted suite of segments, products, and services designed to cater to diverse consumer needs, along with support for research initiatives.
Segments
1. Health and Ancestry Reports:
- Ancestry + Traits Service: This segment enables customers to obtain a comprehensive ethnicity estimate derived from their DNA, offering insights into ancestral origins. Users can explore various ethnic group percentages and trace their lineage.
- Health Risk Reports: These reports provide vital information on genetic predispositions to certain health conditions. The service includes assessments for various genetic health risks, including but not limited to:
- Type 2 Diabetes
- Alzheimer’s Disease
- Parkinson’s Disease
- Certain types of cancer (e.g. breast and ovarian cancer)
- Carrier Status Reports: It helps individuals discover whether they are carriers of genetic mutations that could be passed on to their offspring, influencing decisions regarding family planning.
2. Genetic Counseling:
- This segment centers on offering support and guidance from certified genetic counselors to those who have received test results indicating potential health risks. Counselors assist customers in:
- Understanding test results, their implications, and the significance of genetic findings.
- Discussing further steps, including additional testing or preventive measures.
- Providing personalized advice on managing health risks and lifestyle choices.
Products
1. DNA Testing Kits:
- The flagship product is the DNA testing kit, which includes a saliva collection kit and precise instructions for users to collect their DNA sample. Once the sample is sent back, it undergoes analysis in a laboratory setting. The final results are delivered through an online platform, providing customers access to their genetic information efficiently.
- The DNA testing kits are user-friendly and designed to cater to a variety of age groups, making them accessible to a wide audience.
2. Research Services:
- 23andMe offers a unique research services segment allowing academic and commercial entities to collaborate with the company. Through their research partnerships, institutions can access anonymized genetic data collected via consumer testing. Utilizing this vast dataset, researchers can delve into:
- Population genetics
- Clinical studies
- Drug development processes
- This facet not only bolsters scientific research but also contributes to the larger body of knowledge regarding genetics and health.
Services
1. DNA Testing:
- Beyond the standard reporting that comes with DNA testing, the genetic testing service includes various features such as ethnic background estimation, connections to relatives who have also tested, as well as unique genetic traits (e.g. genetic markers linked to taste preferences).
2. Ancestry Reports:
- In-depth ancestry reports explore not just ethnic composition but also detailed genealogical information. Customers can gain insights into their family history, migration patterns of their ancestors, and even connections to historical populations.
3. Genetic Counseling:
- Following the analytical report, customers with concerning genetic markers can consult with 23andMes genetic counseling team. The service is aimed at offering clarity and support in managing genetic health risks and exploring familial repercussions.
4. Research Participation:
- Engaged customers are offered the chance to partake in research studies that seek to explore various health and genetic topics. By contributing their genetic material and health information, participants help advance the discovery of treatments and understanding of genetic diseases and conditions.
Conclusion
In summary, 23andMe Holding Co emerges as a multifaceted entity within the biotechnology and genetic testing landscape, offering an array of products and services tailored to empower individuals with knowledge about their genetic background and health. Through innovative segments such as health and ancestry reports, alongside professional counseling and research collaboration, the company stands at the forefront of genetic literacy, thereby enabling consumers to make well-informed decisions regarding their health and wellness.
23andMe Holding Co is a pioneering biotechnology and genetic testing company that focuses on empowering individuals to understand their genetic information, emphasizing health and ancestry insights. The company offers a multifaceted suite of segments, products, and services designed to cater to diverse consumer needs, along with support for research initiatives.
Segments
1. Health and Ancestry Reports:
- Ancestry + Traits Service: This segment enables customers to obtain a comprehensive ethnicity estimate derived from their DNA, offering insights into ancestral origins. Users can explore various ethnic group percentages and trace their lineage.
- Health Risk Reports: These reports provide vital information on genetic predispositions to certain health conditions. The service includes assessments for various genetic health risks, including but not limited to:
- Type 2 Diabetes
- Alzheimer’s Disease
- Parkinson’s Disease
- Certain types of cancer (e.g. breast and ovarian cancer)
- Carrier Status Reports: It helps individuals discover whether they are carriers of genetic mutations that could be passed on to their offspring, influencing decisions regarding family planning.
2. Genetic Counseling:
- This segment centers on offering support and guidance from certified genetic counselors to those who have received test results indicating potential health risks. Counselors assist customers in:
- Understanding test results, their implications, and the significance of genetic findings.
- Discussing further steps, including additional testing or preventive measures.
- Providing personalized advice on managing health risks and lifestyle choices.
Products
1. DNA Testing Kits:
- The flagship product is the DNA testing kit, which includes a saliva collection kit and precise instructions for users to collect their DNA sample. Once the sample is sent back, it undergoes analysis in a laboratory setting. The final results are delivered through an online platform, providing customers access to their genetic information efficiently.
- The DNA testing kits are user-friendly and designed to cater to a variety of age groups, making them accessible to a wide audience.
2. Research Services:
- 23andMe offers a unique research services segment allowing academic and commercial entities to collaborate with the company. Through their research partnerships, institutions can access anonymized genetic data collected via consumer testing. Utilizing this vast dataset, researchers can delve into:
- Population genetics
- Clinical studies
- Drug development processes
- This facet not only bolsters scientific research but also contributes to the larger body of knowledge regarding genetics and health.
Services
1. DNA Testing:
- Beyond the standard reporting that comes with DNA testing, the genetic testing service includes various features such as ethnic background estimation, connections to relatives who have also tested, as well as unique genetic traits (e.g. genetic markers linked to taste preferences).
2. Ancestry Reports:
- In-depth ancestry reports explore not just ethnic composition but also detailed genealogical information. Customers can gain insights into their family history, migration patterns of their ancestors, and even connections to historical populations.
3. Genetic Counseling:
- Following the analytical report, customers with concerning genetic markers can consult with 23andMes genetic counseling team. The service is aimed at offering clarity and support in managing genetic health risks and exploring familial repercussions.
4. Research Participation:
- Engaged customers are offered the chance to partake in research studies that seek to explore various health and genetic topics. By contributing their genetic material and health information, participants help advance the discovery of treatments and understanding of genetic diseases and conditions.
Conclusion
In summary, 23andMe Holding Co emerges as a multifaceted entity within the biotechnology and genetic testing landscape, offering an array of products and services tailored to empower individuals with knowledge about their genetic background and health. Through innovative segments such as health and ancestry reports, alongside professional counseling and research collaboration, the company stands at the forefront of genetic literacy, thereby enabling consumers to make well-informed decisions regarding their health and wellness.